These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. Atack JR; Wong DF; Fryer TD; Ryan C; Sanabria S; Zhou Y; Dannals RF; Eng WS; Gibson RE; Burns HD; Vega JM; Vessy L; Scott-Stevens P; Beech JS; Baron JC; Sohal B; Schrag ML; Aigbirhio FI; McKernan RM; Hargreaves RJ J Pharmacol Exp Ther; 2010 Jan; 332(1):17-25. PubMed ID: 19779131 [TBL] [Abstract][Full Text] [Related]
52. ONO-8590580, a Novel GABA Kawaharada S; Nakanishi M; Nakanishi N; Hazama K; Higashino M; Yasuhiro T; Lewis A; Clark GS; Chambers MS; Maidment SA; Katsumata S; Kaneko S J Pharmacol Exp Ther; 2018 Jul; 366(1):58-65. PubMed ID: 29674331 [TBL] [Abstract][Full Text] [Related]
53. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists. Martínez-Cué C; Delatour B; Potier MC Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222 [TBL] [Abstract][Full Text] [Related]
54. In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Van Laere K; Bormans G; Sanabria-Bohórquez SM; de Groot T; Dupont P; De Lepeleire I; de Hoon J; Mortelmans L; Hargreaves RJ; Atack JR; Burns HD Biol Psychiatry; 2008 Jul; 64(2):153-61. PubMed ID: 18339360 [TBL] [Abstract][Full Text] [Related]
55. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Atack JR Adv Pharmacol; 2009; 57():137-85. PubMed ID: 20230761 [TBL] [Abstract][Full Text] [Related]
56. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Koh MT; Rosenzweig-Lipson S; Gallagher M Neuropharmacology; 2013 Jan; 64(1):145-52. PubMed ID: 22732440 [TBL] [Abstract][Full Text] [Related]
57. Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Braudeau J; Dauphinot L; Duchon A; Loistron A; Dodd RH; Hérault Y; Delatour B; Potier MC Adv Pharmacol Sci; 2011; 2011():153218. PubMed ID: 22028705 [TBL] [Abstract][Full Text] [Related]
58. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model. Möhler H Biochem Pharmacol; 2012 Oct; 84(8):994-9. PubMed ID: 22898099 [TBL] [Abstract][Full Text] [Related]
59. Contribution of GABA Paine TA; Chang S; Poyle R Behav Brain Res; 2020 Jan; 378():112261. PubMed ID: 31560920 [TBL] [Abstract][Full Text] [Related]